Development of mechanistic model of Parkinson’s Disease (PD): Modeling and calibration of the α-synuclein pathway

Using QSP model of Rheumatoid Arthiritis, calibrated to capture clinical response to Adalimumab, to perform population analysis

Development of mechanistic mPBPK/QSP Antibody drug conjugates (ADC) platform model with applications across preclinical, translational and clinical stages of drug development

Using an IO QSP Model to re-define efficacy, discontinuation criteria, and biomarker analysis

Comparative study of alternative models capturing target mediated drug disposition (TMDD) for CD40 agonists

Network Meta-Analysis to evaluate comparative efficary, progression free survival and tolerability among Immune Checkpoint Inhibitor Therapies (CIT) in Meanoma patients

Systems Approach to immuno-oncology drug development: Integrating Data & Knowledge